Mass Tort brief
Jury Tests and Gatekeeping Rulings Reshape Mass Tort Dockets
Bayer and J&J test warning claims in state courts while federal judges review causation standards across GLP-1 and cosmetic litigations.
Mass Tort
Bayer's new Missouri trial tests whether state failure-to-warn claims survive appellate pushback — deciding if remaining Roundup liabilities continue mounting or settle.
BackgroundBayer acquired Monsanto in 2018 for $63B, inheriting tens of thousands of personal injury lawsuits alleging glyphosate exposure causes non-Hodgkin lymphoma. The German conglomerate has paid roughly $11B resolving over 100,000 cases while continuing to defend unresolved claims in state courts.
- The Missouri lawsuit was brought by 3 cancer patients alleging Monsanto concealed internal toxicity studies demonstrating cellular damage from glyphosate.
- Bayer's defense team argued that decades of global regulatory approvals from the EPA and international authorities confirm the chemical does not cause cancer.
- The verdict will test Bayer's post-appellate legal strategy as the company seeks to stem state-level liability and cap unresolved claims.
Mass Tort
J&J defeated a key talc mesothelioma lawsuit in Massachusetts — proving juries can find warning deficiencies without awarding multi-million-dollar damages.
BackgroundJohnson & Johnson faces thousands of personal injury lawsuits alleging cosmetic talc products were contaminated with carcinogenic asbestos fibers. J&J replaced talc with cornstarch globally while pursuing a $5.5B prepackaged bankruptcy settlement to resolve roughly 70,000 ovarian cancer claims.
- The Plymouth, Massachusetts jury returned a complete defense verdict, finding no proximate medical causation between talcum powder use and the plaintiff's malignant mesothelioma.
- Jurors determined that Johnson's Baby Powder packaging should have featured caution labels regarding inhalation, yet flatly rejected awarding financial damages because medical causation was unproven.
- The defense victory provides J&J with courtroom momentum as it continues to litigate rare mesothelioma claims separately from its global ovarian cancer settlement.
Mass Tort
Federal courts set September 2027 for the first hair relaxer cancer bellwether trial — giving 32,000 plaintiffs their initial timeline toward potential settlements.
BackgroundThe federal hair relaxer multidistrict litigation consolidated lawsuits from women alleging endocrine-disrupting chemicals like phthalates in straightening products caused uterine and ovarian cancers. Manufacturers including L'Oréal and Revlon contend their cosmetic formulations are safe and supported by scientific testing.
- U.S. District Judge Mary Rowland established the trial timeline to evaluate core scientific causation and corporate liability across the 32,000-case docket.
- Plaintiffs allege cosmetic brands deliberately targeted Black women with aggressive marketing campaigns while privately concealing internal studies on long-term reproductive risks.
- The bellwether trial outcome will serve as the initial pricing benchmark for eventual global settlement negotiations across cosmetic industry defendants.
Mass Tort
Rule 702 hearings wrapped for 4,000 Ozempic injury claims — leaving the future of the multi-billion-dollar GLP-1 litigation in the hands of the presiding judge.
BackgroundBlockbuster GLP-1 diabetes and obesity drugs Ozempic, Wegovy, and Mounjaro delayed gastric emptying to suppress appetite and improve glycemic control. Thousands of patients filed personal injury lawsuits alleging manufacturers failed to warn about severe risks of stomach paralysis and ischemic optic neuropathy.
- U.S. District Judge Karen Marston concluded weeks of Daubert hearings evaluating epidemiologists and gastroenterologists who testified that GLP-1 agonists cause permanent stomach paralysis.
- Novo Nordisk and Eli Lilly argued that clinical trial records and post-market safety data fail to establish a direct causal link to permanent gastroparesis.
- If Judge Marston admits plaintiffs' scientific expert witnesses, the litigation will transition toward scheduling individual bellwether trials against drugmakers.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
